VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Gertz on Expanding Treatment Options for Myeloma

Morie Gertz, MD
Published: Friday, Feb 06, 2015



Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.
 
There are a number of new agents that are being used for the management of myeloma, says Gertz.  Daratumumab, a fully human IgG1k monoclonal antibody that targets CD38, has demonstrated promising activity as monotherapy in patients with relapsed/refractory multiple myeloma.
 
Carfilzomib, lenalidomide, and dexamethasone have been shown to improve progression-free survival. Panobinostat, a deacetylase (DAC) inhibitor is also being used in new ways to treat myeloma.


Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.
 
There are a number of new agents that are being used for the management of myeloma, says Gertz.  Daratumumab, a fully human IgG1k monoclonal antibody that targets CD38, has demonstrated promising activity as monotherapy in patients with relapsed/refractory multiple myeloma.
 
Carfilzomib, lenalidomide, and dexamethasone have been shown to improve progression-free survival. Panobinostat, a deacetylase (DAC) inhibitor is also being used in new ways to treat myeloma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x